JPRN-jRCT2080223713已完成3 期
A phase III, double-blind, placebo-controlled, monotherapy study of imeglimin (TIMES 1)
POXEL S.A./ CMIC Co., Ltd.0 个研究点目标入组 213 人开始时间: 2017年11月13日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 213
研究概览
简要总结
Imeglimin significantly improved HbA1c in Japanese patients with type 2 diabetes compared with placebo and had a similar safety profile to placebo. Imeglimin represents a potential new treatment option for this population.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Main inclusion criteria:
- •1) Patients with type 2 diabetes mellitus, diagnosed for at least 12 weeks
- •2) Body Mass Index (BMI) >= 18.5
- •3) HbA1c >=7.0% and < 10.0%
排除标准
- •Main exclusion criteria:
- •1) Patients with type 1 diabetes mellitus, diabetes that is a result of pancreatic injury, or secondary forms of diabetes
- •2) History of diabetic ketoacidosis or hyperosmolar non-ketotic coma
- •3) Cardiovascular or cerebrovascular disease within 24 weeks (myocardial infarction, stroke, unstable angina etc.)
- •4) Uncontrolled high blood pressure
- •5) Severe impairment of hepatic function
研究者
相似试验
已完成
3 期
TIMES 3Type 2 Diabetes MellitusJPRN-jRCT2080223790POXEL S.A./ CMIC Co., Ltd.215
已完成
4 期
A study to test how well empagliflozin works in Japanese people with type 2 diabetes who are older than 65 yearstype 2 diabetes mellitusJPRN-jRCT1080225321ippon Boehringer Ingelheim Co., Ltd.129
已完成
不适用
Efficacy of Linagliptin in Japanese type 2 diabetic patients in hemodialysisJapanese type 2 diabetic patients in hemodialysisJPRN-UMIN000007716Fukuoka University hospital100
已完成
不适用
Japanese study of Linagliptin for type 2 diabetes patients with NAFLD in KagoshimaType 2 DiabetesJPRN-UMIN000014864Japan society of Patient Reported Outcome48
已完成
4 期
A randomized controlled trial of Ipragliflozin and sitagliptiType 2 diabetesJPRN-jRCTs031180205Sone Hirohito115